NCT06107972

Brief Summary

The purpose of this study is to evaluate the acceptability, feasibility (e.g., satisfaction, completion rate, barriers to recruitment, treatment fidelity) of the culturally refined Launching! to Adulthood (¡Iniciando! la Adultez) program, to test for a preliminary signal of effect between baseline and post-treatment for the Launching! to Adulthood (¡Iniciando! la Adultez) program and to identify preliminary neural mechanisms of action, including biomarkers of brain structure and connectivity, in terms of treatment response for 15 Latino young adults participating in the ¡Iniciando! therapy program.

Trial Health

55
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
56

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Apr 2024

Geographic Reach
1 country

1 active site

Status
active not recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

October 22, 2023

Completed
8 days until next milestone

First Posted

Study publicly available on registry

October 30, 2023

Completed
5 months until next milestone

Study Start

First participant enrolled

April 1, 2024

Completed
1.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 1, 2025

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2025

Completed
Last Updated

August 27, 2025

Status Verified

August 1, 2025

Enrollment Period

1.6 years

First QC Date

October 22, 2023

Last Update Submit

August 26, 2025

Conditions

Outcome Measures

Primary Outcomes (4)

  • Change in adaptive behavior as assessed by the Adaptive Behaviour Assessment System, Third Edition

    This is a 239 item questionnaire and each is scored from 0(is not able to do this behavior) to 3 \[(always able to do this behavior)(or almost always)\] a higher number indicating better outcome

    baseline, mid-treatment (5 weeks after baseline) , post-treatment (12 weeks after baseline), 3 month follow up, 6 month follow up

  • Change in Quality of life as assessed by the Autism Spectrum Quality of Life (ASQoL) questionnaire

    This is a 9 item questionnaire. Questions 1-5 and 9 are each scored from 1(not at all) to 5(totally) a higher number indicating better outcome and questions 6-8 are reverse scored from 5(never) to 1(always) a higher score indicating worse outcome

    baseline, mid-treatment (5 weeks after baseline) , post-treatment (12 weeks after baseline), 3 month follow up, 6 month follow up

  • Change in Anxiety as assessed by the Generalized Anxiety Disorder-7 (GAD7)

    This is a 7 item questionnaire and each is scored from 0(not at all) to 4(nearly every day) for a maximum score of 21 , higher score indicating more anxiety

    baseline, mid-treatment(5 weeks after baseline) , post-treatment (12 weeks after baseline), 3 month follow up, 6 month follow up

  • Change in depression as assessed by the Patient Health Questionnaire (PHQ-9)

    This is a 9 item questionnaire and each is scored from 0(not at all) to 3(nearly every day) for a maximum score of 27, higher number indicating worse outcome

    baseline, mid-treatment(5 weeks after baseline) , post-treatment (12 weeks after baseline), 3 month follow up, 6 month follow up

Secondary Outcomes (4)

  • Change in caregiver burden as assessed by the Rapid Screen for Caregiver Burden (CBI)

    baseline, mid treatment (5 weeks after baseline) , post-treatment (12 weeks after baseline), 3 month follow up, 6 month follow up

  • Change in efficacy of coping with life's challenges as assessed by the Coping Self-Efficacy Scale (CSES)

    baseline, mid treatment (5 weeks after baseline) , post-treatment (12 weeks after baseline),3 month follow up, 6 month follow up

  • Change in stress as assessed by the Riverside Acculturation Stress Inventory (RASI)

    baseline, mid treatment (5 weeks after baseline) , post-treatment (12 weeks after baseline), 3 month follow up, 6 month follow up

  • Change in goal attainment Goal Attainment Scaling (GAS)

    week 1, week 2, week 3, week 4, week 5, week 6, week 7, week 8, week 9, week 10, week 11, week 12

Study Arms (1)

Launching! to Adulthood (¡Iniciando! la Adultez) program

EXPERIMENTAL
Behavioral: Launching! to Adulthood (¡Iniciando! la Adultez) program

Interventions

The program includes cognitive behavioral and acceptance and commitment therapy, with a focus on developing goals during the transition to adulthood through a values framework. After a combined (parents and young adults) 90-minute introductory group meeting in-person, parents and the transition-aged young adults with ASD attend 9 separate, 90-minute weekly group telehealth meetings. Additionally, young adults have weekly personal coaching meetings for 30-minutes to discuss progress toward goals and barriers encountered. Leaders teach transition-aged young adult's skills through various social activities, as well as other skills (e.g., emotion regulation, cognitive diffusion) to help overcome barriers towards their goals. The treatment targets three core factors (i.e., mental health conditions, social skills, and coping with and adapting to stress). Leaders teach parents new parenting skills, knowledge of ASD, and readiness to support their young adult's transition to independent life.

Launching! to Adulthood (¡Iniciando! la Adultez) program

Eligibility Criteria

Age18 Years - 25 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • confirmed case of ASD
  • a score of \>14 on the Social Communication Questionnaire-Lifetime (SCQ-L110) completed with the mother or father
  • meet DSM-5 criteria for ASD based on a Diagnostic and Statistical Manual of Mental Disorders (DSM)-5 ASD symptom checklist
  • previous diagnosis of ASD from a licensed mental health or medical professional
  • speak English
  • have a parent willing to participate
  • score \>85 on verbal intelligence quotient (IQ) on the Kaufman Brief Intelligence Test (KBIT-2)

You may not qualify if:

  • history of a psychotic disorder or current psychotic symptoms
  • suicidal ideation with intent or plan
  • current alcohol or other substance use disorder rated severe
  • concurrent enrollment in another clinical trial for autism spectrum disorder
  • expression of unwillingness to complete study procedures
  • For fMRI, unable to undergo fMRI scanning due to metallic devices or objects (cardiac pacemaker or neurostimulator, some artificial joints, metal pins, surgical clips, or other implanted metal parts) or claustrophobic to the scanner.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

The University of Texas Health Science Center at Houston

Houston, Texas, 77030, United States

Location

MeSH Terms

Conditions

Autism Spectrum Disorder

Condition Hierarchy (Ancestors)

Child Development Disorders, PervasiveNeurodevelopmental DisordersMental Disorders

Study Officials

  • Antonio Pagan, PhD

    The University of Texas Health Science Center, Houston

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Postdoctoral Research Fellow

Study Record Dates

First Submitted

October 22, 2023

First Posted

October 30, 2023

Study Start

April 1, 2024

Primary Completion

November 1, 2025

Study Completion

December 31, 2025

Last Updated

August 27, 2025

Record last verified: 2025-08

Data Sharing

IPD Sharing
Will not share

Locations